AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Appliances & Equipment
- Sub-Industry: N/A
- Symbol: NASDAQ:AXGN
- CUSIP: N/A
- Web: www.axogeninc.com
Capitalization:- Market Cap: $618.26 million
- Outstanding Shares: 33,240,000
Average Prices:- 50 Day Moving Avg: $16.58
- 200 Day Moving Avg: $14.19
- 52 Week Range: $7.65 - $19.20
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -206.67
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $50.02 million
- Price / Sales: 12.36
- Book Value: $0.34 per share
- Price / Book: 54.71
Profitability:- EBIDTA: ($8,050,000.00)
- Net Margins: -27.50%
- Return on Equity: -114.64%
- Return on Assets: -27.71%
Debt:- Debt-to-Equity Ratio: 1.80%
- Current Ratio: 3.67%
- Quick Ratio: 3.09%
Misc:- Average Volume: 206,988 shs.
- Beta: 0.23
- Short Ratio: 5.8
Frequently Asked Questions for AxoGen (NASDAQ:AXGN)
What is AxoGen's stock symbol?
AxoGen trades on the NASDAQ under the ticker symbol "AXGN."
How were AxoGen's earnings last quarter?
AxoGen, Inc. (NASDAQ:AXGN) posted its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.06) EPS for the quarter, topping the Zacks' consensus estimate of ($0.08) by $0.02. The firm earned $15.20 million during the quarter, compared to analyst estimates of $14.40 million. AxoGen had a negative return on equity of 114.64% and a negative net margin of 27.50%. The business's revenue for the quarter was up 46.2% on a year-over-year basis. During the same period last year, the company earned ($0.09) earnings per share. View AxoGen's Earnings History.
When will AxoGen make its next earnings announcement?
Where is AxoGen's stock going? Where will AxoGen's stock price be in 2017?
6 analysts have issued 1 year target prices for AxoGen's shares. Their forecasts range from $11.00 to $22.00. On average, they anticipate AxoGen's stock price to reach $17.20 in the next twelve months. View Analyst Ratings for AxoGen.
Who are some of AxoGen's key competitors?
Some companies that are related to AxoGen include LHC Group (LHCG), Aimmune Therapeutics (AIMT), Natus Medical Incorporated (BABY), Irhythm Tech (IRTC), Mazor Robotics (MZOR), Sangamo Therapeutics (SGMO), Ascendis Pharma A/S (ASND), Esperion Therapeutics (ESPR), Glaukos Corporation (GKOS), Acorda Therapeutics (ACOR), Dermira (DERM), The Ensign Group (ENSG), Genomic Health (GHDX), BioTelemetry (BEAT), Xencor (XNCR), NeuroDerm (NDRM), ABAXIS (ABAX) and Omeros Corporation (OMER).
Who owns AxoGen stock?
AxoGen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.68%), Russell Investments Group Ltd. (1.85%), Gilder Gagnon Howe & Co. LLC (1.72%), Perkins Capital Management Inc. (1.68%), State Street Corp (1.32%) and Castleark Management LLC (0.97%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, James E Flynn, John P Engels, Joseph M Mandato, Karen L Zaderej, Peter J Mariani and Robert James Rudelius. View Institutional Ownership Trends for AxoGen.
Who sold AxoGen stock? Who is selling AxoGen stock?
AxoGen's stock was sold by a variety of institutional investors in the last quarter, including Summit Partners Public Asset Management LLC, Pennsylvania Trust Co, Suffolk Capital Management LLC, Perkins Capital Management Inc., S Squared Technology LLC, Timpani Capital Management LLC, Granite Point Capital Management L.P. and California State Teachers Retirement System. View Insider Buying and Selling for AxoGen.
Who bought AxoGen stock? Who is buying AxoGen stock?
AxoGen's stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Castleark Management LLC, EAM Investors LLC, Vanguard Group Inc., Lyon Street Capital LLC, Ameriprise Financial Inc., Parametric Portfolio Associates LLC and State Street Corp. Company insiders that have bought AxoGen stock in the last two years include Amy Mcbride Wendell, John P Engels, Karen L Zaderej and Peter J Mariani. View Insider Buying and Selling for AxoGen.
How do I buy AxoGen stock?
Shares of AxoGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AxoGen's stock price today?
One share of AxoGen stock can currently be purchased for approximately $18.60.
MarketBeat Community Rating for AxoGen (NASDAQ AXGN)MarketBeat's community ratings are surveys of what our community members think about AxoGen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for AxoGen (NASDAQ:AXGN)Earnings History by Quarter for AxoGen (NASDAQ AXGN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/31/2017 | | ($0.06) | | | | | N/A |  |
| 8/2/2017 | Q2 2017 | ($0.08) | ($0.06) | $14.40 million | $15.20 million | View | Listen | |
| 5/4/2017 | Q1 2017 | ($0.10) | ($0.11) | $11.83 million | $12.24 million | View | Listen | |
| 2/22/2017 | Q4 2016 | ($0.09) | ($0.10) | | $11.41 million | View | Listen | |
| 11/2/2016 | Q3 2016 | ($0.08) | ($0.08) | $11.21 million | $11.21 million | View | N/A | |
| 8/3/2016 | Q2 | ($0.12) | ($0.09) | $9.28 million | $10.38 million | View | N/A | |
| 11/5/2015 | Q3 2015 | ($0.12) | ($0.11) | $6.70 million | $8.15 million | View | N/A | |
| 8/6/2015 | Q2 2015 | ($0.15) | ($0.13) | $5.89 million | $6.42 million | View | N/A | |
| 5/5/2015 | Q1 2015 | ($0.17) | ($0.16) | $4.90 million | $4.95 million | View | N/A | |
| 11/13/2014 | Q3 2014 | ($0.24) | ($0.19) | | $4.67 million | View | N/A | |
| 8/4/2014 | Q2 2014 | ($0.22) | ($0.21) | $3.30 million | $4.21 million | View | N/A | |
| 4/30/2014 | Q1 2014 | ($0.26) | ($0.24) | $2.75 million | $3.14 million | View | N/A | |
| 3/6/2014 | | ($0.22) | ($0.24) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for AxoGen (NASDAQ:AXGN)2017 EPS Consensus Estimate: ($0.29)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | ($0.12) | ($0.07) | ($0.10) |
| Q2 2017 | 3 | ($0.06) | ($0.04) | ($0.05) |
| Q3 2017 | 4 | ($0.10) | ($0.03) | ($0.06) |
| Q4 2017 | 3 | ($0.14) | ($0.04) | ($0.08) |
| Q1 2018 | 2 | ($0.10) | $0.01 | ($0.05) |
| Q2 2018 | 2 | ($0.05) | $0.03 | ($0.01) |
| Q3 2018 | 1 | $0.04 | $0.04 | $0.04 |
(Data provided by Zacks Investment Research)
Dividend History for AxoGen (NASDAQ:AXGN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for AxoGen (NASDAQ:AXGN)Insider Ownership Percentage: 9.33%
Institutional Ownership Percentage: 66.77%
Insider Trades by Quarter for AxoGen (NASDAQ:AXGN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/11/2017 | Robert James Rudelius | Director | Sell | 16,143 | $18.00 | $290,574.00 | |
| 10/7/2016 | Amy Mcbride Wendell | Director | Buy | 13,333 | $7.50 | $99,997.50 | |
| 10/7/2016 | John P Engels | VP | Buy | 4,000 | $7.50 | $30,000.00 | |
| 10/7/2016 | Karen L Zaderej | CEO | Buy | 10,000 | $7.50 | $75,000.00 | |
| 10/7/2016 | Peter J Mariani | CFO | Buy | 3,333 | $7.50 | $24,997.50 | |
| 8/9/2016 | Joseph M Mandato | Director | Sell | 149,618 | $8.54 | $1,277,737.72 | |
| 8/8/2016 | Joseph M Mandato | Director | Sell | 107,450 | $8.63 | $927,293.50 | |
| 7/21/2016 | James E Flynn | Insider | Sell | 102,136 | $6.70 | $684,311.20 | |
| 7/18/2016 | James E Flynn | Insider | Sell | 279,303 | $7.53 | $2,103,151.59 | |
| 9/18/2015 | James E Flynn | Insider | Sell | 345,000 | $5.50 | $1,897,500.00 | |
| 6/3/2015 | Joseph M Mandato | Director | Buy | 6,500 | $3.10 | $20,150.00 | |
| 6/2/2015 | Lee Robert Johnston Jr | Insider | Buy | 5,000 | $3.06 | $15,300.00 | |
| 4/8/2015 | James E Flynn | Insider | Sell | 144,385 | $3.25 | $469,251.25 | |
| 12/10/2014 | Lee Robert Johnston Jr | CFO | Buy | 10,000 | $3.06 | $30,600.00 | |
| 8/12/2014 | Mark Stephen Gold | Director | Buy | 20,000 | $2.29 | $45,800.00 | |
| 8/8/2014 | Mark Stephen Gold | Director | Buy | 11,000 | $2.31 | $25,410.00 | |
| 6/6/2014 | Lee Robert Johnston Jr | CFO | Buy | 10,000 | $2.58 | $25,800.00 | |
| 6/3/2014 | Gregory Gene Freitag | CFO | Buy | 5,200 | $2.45 | $12,740.00 | |
| 6/3/2014 | Karen L Zaderej | CEO | Buy | 5,000 | $2.43 | $12,150.00 | |
| 5/20/2014 | Jill F Schiaparelli | SVP | Buy | 2,000 | $2.63 | $5,260.00 | |
| 5/12/2014 | Karen L Zaderej | CEO | Buy | 5,000 | $2.70 | $13,500.00 | |
| 5/7/2014 | Mark Stephen Gold | Director | Buy | 1,977 | $2.60 | $5,140.20 | |
| 3/13/2014 | Karen L Zaderej | CEO | Buy | 1,500 | $3.49 | $5,235.00 | |
| 8/29/2013 | Shawn F Mccarrey | SVP | Buy | 25,000 | $3.21 | $80,250.00 | |
| 8/24/2013 | Shawn F Mccarrey | SVP | Buy | 5,000 | $3.00 | $15,000.00 | |
| 8/14/2013 | Jill F Schiaparelli | SVP | Buy | 5,000 | $3.00 | $15,000.00 | |
| 8/14/2013 | John Frederick Harper | Director | Buy | 66,666 | $3.00 | $199,998.00 | |
| 8/14/2013 | Karen L Zaderej | CEO | Buy | 8,334 | $3.00 | $25,002.00 | |
| 12/4/2012 | Jill F Schiaparelli | SVP | Buy | 2,000 | $2.55 | $5,100.00 | |
| 11/29/2012 | Jill F Schiaparelli | SVP | Buy | 1,000 | $2.70 | $2,700.00 | |
| 11/15/2012 | Jill F Schiaparelli | SVP | Buy | 2,750 | $2.56 | $7,040.00 | |
| 10/1/2012 | John Frederick Harper | Director | Buy | 86,557 | $3.61 | $312,470.77 | |
(Data available from 1/1/2013 forward)
Headline Trends for AxoGen (NASDAQ:AXGN)
Latest Headlines for AxoGen (NASDAQ:AXGN)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to AxoGen, Inc. : September 22, 2017
finance.yahoo.com - September 22 at 12:56 PM |
 | Zacks: Analysts Anticipate AxoGen, Inc. (AXGN) Will Announce Quarterly Sales of $15.58 Million
www.americanbankingnews.com - September 17 at 2:00 AM |
| AxoGen, Inc. (AXGN) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 13 at 6:38 AM |
| Robert James Rudelius Sells 16,143 Shares of AxoGen, Inc. (AXGN) Stock
www.americanbankingnews.com - September 12 at 7:52 PM |
| AxoGen, Inc. (AXGN) Stock Rating Reaffirmed by Roth Capital
www.americanbankingnews.com - September 12 at 9:30 AM |
| ETFs with exposure to AxoGen, Inc. : September 12, 2017
finance.yahoo.com - September 11 at 9:51 PM |
| AxoGen, Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 11 at 4:49 PM |
| AxoGen, Inc. :AXGN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 8, 2017
finance.yahoo.com - September 8 at 9:41 PM |
| AxoGen, Inc. (AXGN) Expected to Post Earnings of -$0.08 Per Share
www.americanbankingnews.com - August 28 at 12:24 PM |
| AxoGen to Participate at 72nd Annual American Society for Surgery of the Hand Meeting
finance.yahoo.com - August 24 at 4:20 PM |
| Cantor Fitzgerald Reiterates "Buy" Rating for AxoGen, Inc. (AXGN)
www.americanbankingnews.com - August 21 at 8:28 PM |
 | AxoGen (AXGN): Key Points From Non Deal Roadshow - Cantor
www.streetinsider.com - August 21 at 4:16 PM |
| AxoGen, Inc. (AXGN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 19 at 6:50 AM |
| AxoGen, Inc. breached its 50 day moving average in a Bullish Manner : AXGN-US : August 15, 2017
finance.yahoo.com - August 15 at 5:12 PM |
| Financial Comparison: Medtronic PLC (MDT) vs. AxoGen (AXGN)
www.americanbankingnews.com - August 15 at 12:38 PM |
| AxoGen, Inc. (NASDAQ:AXGN) Expected to Announce Quarterly Sales of $15.58 Million
www.americanbankingnews.com - August 12 at 7:22 PM |
| AxoGen, Inc. – Value Analysis (NASDAQ:AXGN) : August 11, 2017
finance.yahoo.com - August 11 at 9:45 PM |
| FY2017 EPS Estimates for AxoGen, Inc. Raised by Cantor Fitzgerald (NASDAQ:AXGN)
www.americanbankingnews.com - August 10 at 1:50 PM |
| Analysts Expect AxoGen, Inc. (NASDAQ:AXGN) Will Announce Earnings of -$0.08 Per Share
www.americanbankingnews.com - August 10 at 8:06 AM |
| Q3 2017 Earnings Estimate for AxoGen, Inc. Issued By Wedbush (AXGN)
www.americanbankingnews.com - August 7 at 8:09 AM |
| Q3 2017 EPS Estimates for AxoGen, Inc. (AXGN) Reduced by Analyst
www.americanbankingnews.com - August 7 at 8:08 AM |
| AxoGen, Inc. (AXGN) Forecasted to Post FY2019 Earnings of $0.16 Per Share
www.americanbankingnews.com - August 4 at 7:40 PM |
| Edited Transcript of AXGN earnings conference call or presentation 2-Aug-17 8:30pm GMT
finance.yahoo.com - August 3 at 5:41 PM |
| AxoGen, Inc. (AXGN) Releases Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - August 3 at 3:38 PM |
| AxoGen reports 2Q loss
finance.yahoo.com - August 2 at 10:02 PM |
| AxoGen, Inc. Reports 2017 Second Quarter Financial Results
finance.yahoo.com - August 2 at 5:00 PM |
| AxoGen, Inc. to Present at the Wedbush PacGrow Healthcare Conference
finance.yahoo.com - July 31 at 4:21 PM |
| AxoGen, Inc. (AXGN) Downgraded by BidaskClub to "Buy"
www.americanbankingnews.com - July 29 at 8:34 PM |
| Comparing Medtronic PLC (MDT) & AxoGen (AXGN)
www.americanbankingnews.com - July 29 at 2:09 PM |
| AxoGen, Inc. breached its 50 day moving average in a Bearish Manner : AXGN-US : July 28, 2017
finance.yahoo.com - July 28 at 5:38 PM |
| AxoGen (AXGN) versus Integer Holdings (ITGR) Head to Head Survey
www.americanbankingnews.com - July 27 at 6:38 PM |
| AxoGen, Inc. (AXGN) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:56 AM |
| AxoGen, Inc. (NASDAQ:AXGN) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 25 at 8:24 AM |
| Zacks: Brokerages Anticipate AxoGen, Inc. (NASDAQ:AXGN) Will Post Quarterly Sales of $14.40 Million
www.americanbankingnews.com - July 22 at 8:00 AM |
| Analysts Anticipate AxoGen, Inc. (NASDAQ:AXGN) to Post -$0.08 EPS
www.americanbankingnews.com - July 20 at 10:18 PM |
| AxoGen, Inc. Discloses Terms of Recent Equity Award
finance.yahoo.com - July 20 at 5:44 PM |
| Globus Medical (GMED) & AxoGen (NASDAQ:AXGN) Critical Review
www.americanbankingnews.com - July 20 at 5:21 PM |
 | AxoGen, Inc. to Report Second Quarter 2017 Financial Results and Host Conference Call on Wednesday,
www.nasdaq.com - July 19 at 5:29 PM |
| AxoGen, Inc. to Report Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, August 2, 2017
finance.yahoo.com - July 19 at 5:29 PM |
| Integer Holdings (ITGR) & AxoGen (NASDAQ:AXGN) Head to Head Analysis
www.americanbankingnews.com - July 16 at 12:26 PM |
| Comparing Sunshine Heart (SSH) & AxoGen (NASDAQ:AXGN)
www.americanbankingnews.com - July 16 at 12:28 AM |
| Reviewing Sunshine Heart (SSH) and AxoGen (NASDAQ:AXGN)
www.americanbankingnews.com - July 15 at 10:04 PM |
| Reviewing Globus Medical (GMED) and AxoGen (NASDAQ:AXGN)
www.americanbankingnews.com - July 15 at 8:07 AM |
| AxoGen, Inc. (NASDAQ:AXGN) Forecasted to Earn FY2017 Earnings of ($0.30) Per Share
www.americanbankingnews.com - July 6 at 9:38 AM |
| AxoGen, Inc. (AXGN) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - June 29 at 6:40 PM |
| AxoGen, Inc. (AXGN) Receives New Coverage from Analysts at Cantor Fitzgerald
www.americanbankingnews.com - June 29 at 6:02 PM |
| AxoGen (AXGN) & Integer Holdings (ITGR) Head to Head Review
www.americanbankingnews.com - June 29 at 8:05 AM |
| $14.40 Million in Sales Expected for AxoGen, Inc. (AXGN) This Quarter
www.americanbankingnews.com - June 28 at 10:34 AM |
| AxoGen, Inc. (AXGN) Expected to Announce Earnings of -$0.08 Per Share
www.americanbankingnews.com - June 26 at 6:38 PM |
 | AxoGen (AXGN) Presents at JMP Securities Life Sciences Conference 2017 - Slideshow
seekingalpha.com - June 22 at 3:52 PM |
AxoGen (AXGN) Chart for Sunday, September, 24, 2017
